Adaptive Immunity and Alzheimer's Disease: Dual Roles in Neurodegeneration and Neuroprotection with Therapeutic Implications.

Biomol Ther (Seoul) · 2026 · PMC12782867 · PMID 41490988

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the corresponding phase I, single-center, open-label trial of Aβ+ hTregs (VT301), intravenous administration of Aβ+ hTregs to patients with mild-to-moderate AD demonstrated safety and feasibility, although efficacy did not reach statistical significance ( Yang et al ., 2024a ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.